Orforglipron
First oral non-peptide GLP-1 receptor agonist (Eli Lilly); Phase 3 obesity program.
Appetite or glycemic effects within the first days; full effect accrues over weeks to months alongside titration.
Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.
Clinical Evidence
What the literature says
Scientific Overview
Orforglipron (LY3502970) is Eli Lilly's small-molecule, non-peptide GLP-1R agonist. Unlike oral semaglutide it does not require SNAC absorption enhancers or fasted dosing. Phase 2 obesity (2023) showed up to 14.7% weight loss at 36 weeks. Phase 3 ATTAIN and ACHIEVE programs read out in 2025.
Citations (3)
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity TreatmentPubMed
- Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 DiabetesReview
- Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trialReview
Research Guide
How users approach this compound
The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.
Research Protocols
Common DosagesInvestigational
“Phase 3 dose range”
Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.
Key Research Benefits
- Oral once-daily dosing
- No food/water restrictions
- Weight loss comparable to injectable GLP-1s in Phase 2
Potential Side Effects
Labs to monitor
Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.
- HbA1c: Primary glycemic efficacy marker for incretin therapy.
- Fasting glucose: Tracks glycemic response and hypoglycemia risk in combination therapy.
- Lipid panel / ApoB: Incretin therapy commonly improves atherogenic lipids alongside weight loss.
Dose Calculator
Peptide Reconstitution Calculator
Total amount of peptide in the vial.
Volume of water used to mix.
Draw to this mark
or 4.80 mL on a U-100 syringe
Orforglipron by goal
Read Orforglipron's profile filtered through specific research goals.
Related Tools
Not medical advice
Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.